Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

Zacks2024-11-30

Key Takeaways Roche announced plans to acquire Poseida Therapeutics for about $1 billion. Merck, AstraZeneca and Novartis have all seen success in studies of new drugs in their pipelines. Register ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487151878?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","is_english":true,"pubTime":"2024-11-30 04:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2487151878","market":"us","top_or_hot":-1,"title":"Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success","media":"Zacks","content":"<div>\n<p>Key Takeaways\n\nRoche announced plans to acquire Poseida Therapeutics for about $1 billion.\nMerck, AstraZeneca and Novartis have all seen success in studies of new drugs in their pipelines.\nRegister ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-buy-200000767.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-30 04:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-buy-200000767.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Takeaways\n\nRoche announced plans to acquire Poseida Therapeutics for about $1 billion.\nMerck, AstraZeneca and Novartis have all seen success in studies of new drugs in their pipelines.\nRegister ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-buy-200000767.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0070302665.USD","symbol_name":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-buy-200000767.html","article_id":"2487151878","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487151878","pubTimestamp":1732910400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Roche announced plans to acquire Poseida Therapeutics for about $1 billion.Merck, AstraZeneca and Novartis have all seen success in studies of new drugs in their pipelines.This week, Roche RHHBY announced that it will acquire its existing partner, Poseida Therapeutics PSTX for $9 per share in cash, representing a total equity value of approximately $1.0 billion. Merck MRK and AstraZeneca’s AZN late-stage studies, evaluating the expanded use of their new drugs, met their respective goals. The European Commission approved Novartis’ NVS breast cancer drug Kisqali  for a broad population in early breast cancer.Based on the overwhelming efficacy seen in the study, an independent data monitoring committee  recommended the study be stopped early. The DMC also recommended that patients with this advanced form of PAH be offered the opportunity to get Winrevair through an open-label extension study.Roche announced a definitive agreement to acquire Poseida Therapeutics, a biotech making allogenei","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","MBC":"MasterBrand, Inc.","RHHBY":"罗氏控股","FC":"富兰克林柯维","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4201":"综合性石油与天然气企业","LU0238689110.USD":"贝莱德环球动力股票基金","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","NVS":"诺华","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","MRK":"默沙东","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4139":"生物科技","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","ADT":"Adt Inc.","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4559":"巴菲特持仓","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","CVR":"芝加哥机械","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PSTX":"Poseida Therapeutics, Inc.","EC":"哥伦比亚国家石油","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","AZN":"阿斯利康","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","EBC":"Eastern Bankshares Inc","BK4086":"建筑产品","LU0058720904.USD":"联博国际健康护理基金A","03165":"华夏欧优股对冲","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"制药股综述：RHHBY将收购PSTX、MRK、AZN，看到管道成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADT":1,"MBC":1,"MRK":1,"NVS":1,"PSTX":1,"FC":1,"EC":1,"EBC":1,"CVR":1,"AZN":1,"RHHBY":1,"03165":0.6},"content_text":"Key Takeaways\n\nRoche announced plans to acquire Poseida Therapeutics for about $1 billion.\nMerck, AstraZeneca and Novartis have all seen success in studies of new drugs in their pipelines.\nRegister now to see our 7 Best Stocks for the Next 30 Days report - free today!\n\n\nThis week, Roche RHHBY announced that it will acquire its existing partner, Poseida Therapeutics PSTX for $9 per share in cash, representing a total equity value of approximately $1.0 billion. Merck MRK and AstraZeneca’s AZN late-stage studies, evaluating the expanded use of their new drugs, met their respective goals. The European Commission approved Novartis’ NVS breast cancer drug Kisqali (ribociclib) for a broad population in early breast cancer.\nHere's a recap of the week’s most important stories.\nMRK’s Study of Winrevair in Advanced PAH Succeeds\nMerck announced positive top-line data from a phase III study, ZENITH, evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair (sotatercept), for more advanced disease – those with WHO Group 1 functional class (FC) III or IV at high risk of mortality. The study met its primary endpoint of time to first morbidity or mortality event, which could be either all-cause death, lung transplantation or PAH hospitalizations. In the study, treatment with Winrevair added to background PAH therapy led to a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo.\nBased on the overwhelming efficacy seen in the study, an independent data monitoring committee (DMC) recommended the study be stopped early. The DMC also recommended that patients with this advanced form of PAH be offered the opportunity to get Winrevair through an open-label extension study.\nWinrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.\nNVS’ Kisqali Gets EU Nod for Early Breast Cancer \nThe European Commission (EC) granted approval to Novartis’ breast cancer drug Kisqali (ribociclib) for a broader patient population. Kisqali can now be prescribed in the EU in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adults with HR+/HER2- early breast cancer (EBC) at a high risk of disease recurrence. The approval is based on data from the phase III NATALEE study. Kisqali was approved for EBC patients in the United States by the FDA in September 2024. Kisqali is already approved for the treatment of metastatic breast cancer (MBC) in several countries.\nRoche to Buy CAR-T Cell Therapy Maker Poseida \nRoche announced a definitive agreement to acquire Poseida Therapeutics, a biotech making allogeneic pre-clinical and clinical-stage CAR-T therapies across areas like hematological malignancies, solid tumors and autoimmune disease. Roche and Poseida already have a collaboration deal to develop off-the-shelf CAR-T cell therapies for hematological malignancies. Roche will acquire Poseida for $9.00 per share in cash at closing plus a non-tradeable contingent value right (CVR) for up to an aggregate of $4.00 per share in cash, adding up to a deal value of approximately $1.5 billion. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.\nRoche also announced that its phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq in a non-small cell lung cancer (NSCLC) indication, did not achieve its primary endpoint of overall survival at the final analysis.\nAZN’s Truqap Combo Improves PFS in Prostate Cancer Study\nAstraZeneca’s phase III study evaluating Truqap in combination with J&J’s Zytiga (abiraterone) and androgen deprivation therapy (ADT) in PTEN-deficient metastatic hormone-sensitive prostate cancer met its primary endpoint of radiographic progression-free survival(rPFS). Data from the CAPItello-281 study showed that the Truqap combination led to a statistically significant and clinically meaningful improvement in rPFS compared to abiraterone and ADT with placebo in patients suffering from this aggressive form of prostate cancer. Truqap is presently approved for treating HR-positive (or ER-positive), HER2-negative locally advanced or metastatic breast cancer.\nThe NYSE ARCA Pharmaceutical Index rose 3.7% in the past five trading sessions.\n\nLarge Cap Pharmaceuticals Industry 5YR % Return\n\nLarge Cap Pharmaceuticals Industry 5YR % Return\n\nHere’s how the eight major stocks performed in the previous five trading sessions.\nImage Source: Zacks Investment Research\nIn the last five trading sessions, all the stocks were in the green. AbbVie rose the most (9.1%).\nIn the past six months, while AbbVie rose the most (17.2%), Novo Nordisk declined the most (20.0%).\n(See the last pharma stock roundup here: Pharma Stock Roundup: EU Nod for PFE’s Hympavzi, NVS Ups Sales View)\nWhat's Next in the Pharma World?\nWatch this space for regular pipeline and regulatory updates next week.\nAstraZeneca, Novartis, Merck and Roche have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAstraZeneca PLC (AZN) : Free Stock Analysis Report\nNovartis AG (NVS) : Free Stock Analysis Report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nPoseida Therapeutics, Inc. (PSTX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487151878"}